NCT03082534 · OUTCOME

Correlative Analyses

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma · Source last updated 2026-10-01

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Newly obtained tumor specimen within 42 days of screening (when feasible)

What was measured

Whole exome sequencing for neoantigen discovery

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Whole exome sequencing for neoantigen discovery
reporting Status: NOT_POSTED
time Frame: Newly obtained tumor specimen within 42 days of screening (when feasible)
title: Correlative Analyses
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice